Strides Pharma Science
Strides Pharma Science is an Indian pharmaceutical company that develops and manufactures generic medicines, over-the-counter products, nutraceuticals, and selected injectable and capsule-based formulations.
Last updated October 29, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Strides Pharma Science Limited is an Indian pharmaceutical company headquartered in Bengaluru. Its business is centered on the development, manufacture, and international supply of generic medicines, over-the-counter products, nutraceuticals, and pharmaceutical formulations. The company has manufactured products in several dosage forms, including softgel capsules, hard-gel capsules, tablets, ointments, and dry and wet injectables. Its portfolio and manufacturing capabilities have supported partnerships with generic-drug companies serving retail pharmacies and hospitals, particularly in injectable products and softgels. The company has operated an internationally distributed manufacturing network, with 15 manufacturing sites across six countries described in the reference material and commercial activity in approximately 50 countries. Its Indian operations have included the KRSG Anekal facility near Bengaluru, which produces soft gelatin capsules, hard gelatin capsules, tablets, and ointments, as well as Strides Technology & Research, an R&D center on Bannerghatta Road in Bengaluru. Its international manufacturing footprint has included Beltapharm S.p.A. in Italy. Strides has also participated in public-health-oriented generic medicine supply. It has worked with the Clinton Foundation's HIV/AIDS initiative to provide lower-cost antiretroviral medicines and has been listed among World Health Organization prequalified suppliers for generic fixed-dose combinations used in HIV treatment. The company has additionally been described as an approved supplier to institutions and programs including the World Bank, the African Development Bank, the U.S. President's Emergency Plan for AIDS Relief, and UNICEF. These activities place the company within the international access-to-medicines and essential-generics ecosystem. A major strategic turning point came with the disposal of the Agila Specialties division to Mylan. Strides announced completion of the transaction in December 2013 for consideration of up to US$1.75 billion. The transaction separated a significant specialty-injectables business from the remaining company and became an important portfolio event in Strides' corporate history. Another major corporate change followed the combination of Strides Arcolab and Shasun Pharmaceuticals. In September 2014, the boards of both companies approved a scheme of amalgamation. Following the transaction, Strides Arcolab adopted the name Strides Shasun, and the business later became known as Strides Pharma Science. The company's public identity therefore reflects both its original Strides heritage and its post-amalgamation corporate development. Arun Kumar is identified as the founder and chairman and has served on the board as managing director since the company's inception. Strides Pharma Science remains an India-based, internationally oriented pharmaceutical manufacturer whose capabilities span formulation development, regulated and emerging-market supply, contract and partnership manufacturing, and public-health-focused generic medicines.
History
Strides Pharma Science developed as an Indian pharmaceutical company with its corporate base in Bengaluru and an outward-looking manufacturing and marketing model. Under founder Arun Kumar, the company built capabilities across pharmaceutical formulation categories rather than concentrating on a single therapeutic area. Its manufacturing portfolio has included softgel and hard-gel capsules, tablets, ointments, and dry and wet injectables, alongside over-the-counter medicines and nutraceuticals. The company expanded through a combination of manufacturing investment, international operations, and partnerships with generic-pharmaceutical companies. Its stated commercial reach has included approximately 50 countries, supported by manufacturing sites in six countries. In India, the KRSG Anekal plant near Bengaluru has produced soft gelatin capsules, hard gelatin capsules, tablets, and ointments. The company has also maintained the Strides Technology & Research facility on Bannerghatta Road in Bengaluru as an R&D center. Outside India, its manufacturing presence has included the Italian company Beltapharm S.p.A. Strides' international role has included the supply of medicines for major public-health needs. The company has participated in generic programs addressing HIV/AIDS, tuberculosis, and malaria. Through work with the Clinton Foundation's HIV/AIDS initiative, it supplied lower-cost antiretroviral medicines. It has also been identified as a World Health Organization prequalified supplier for generic fixed-dose combinations used in HIV treatment. Its stated institutional customer and supplier relationships have included the World Bank, the African Development Bank, PEPFAR, and UNICEF. The company's corporate structure changed significantly in December 2013, when it completed the sale of the Agila Specialties division to Mylan. The transaction was announced at a total value of up to US$1.75 billion. Agila was associated with specialty pharmaceutical and injectable capabilities, so the disposal represented a substantial portfolio reconfiguration and reduced the scope of Strides' direct ownership of that business. In September 2014, Strides Arcolab and Shasun Pharmaceuticals moved toward a broader corporate combination. The boards of both companies approved a scheme of amalgamation, after which Strides Arcolab changed its name to Strides Shasun. This combination became a defining stage in the company's corporate history and preceded the later use of the Strides Pharma Science name. The resulting business retained an emphasis on generic and formulation-based pharmaceuticals, with capabilities serving both retail and hospital channels. Its softgel and injectable expertise has supported partnerships with generic companies, while its consumer-health and nutraceutical activities have broadened the product mix. The company continues to be associated with Indian pharmaceutical manufacturing, international generic-drug supply, and access-to-medicines programs. Arun Kumar is identified as founder and chairman and has also served as managing director since the company's inception.
- 2014
Strides Arcolab and Shasun approve amalgamation
[1]The boards of Strides Arcolab and Shasun Pharmaceuticals approved a scheme of amalgamation.
- 2014
Corporate name changes to Strides Shasun
[1]Following the combination with Shasun Pharmaceuticals, Strides Arcolab adopted the Strides Shasun name.
- 2013
Agila Specialties sale completed
[1]Strides completed the sale of its Agila Specialties division to Mylan for total consideration of up to US$1.75 billion.
Products and positioning
An India-based international pharmaceutical manufacturer focused on generic medicines, differentiated dosage forms, softgels, injectables, consumer-health products, and access-oriented supply partnerships.
Prescription generics
Generic pharmaceuticals
Strides develops and manufactures generic medicines for international markets, supplying products through retail-pharmacy and hospital channels. Its generic portfolio is associated with multiple dosage forms and includes medicines used in public-health programs addressing HIV/AIDS, tuberculosis, and malaria. The company works with generic-pharmaceutical partners as part of its international commercial model.
Pharmaceutical formulations
Softgel capsules
Softgel capsules are one of Strides' principal formulation capabilities. The company has manufactured softgels for pharmaceutical and consumer-health applications and has partnered with generic companies to supply softgel products. This dosage-form expertise forms part of the company's differentiated manufacturing proposition.
Hospital pharmaceuticals
Injectable generics
Strides has manufactured both dry and wet injectables and has supplied injectable products through partnerships with generic companies. These products are positioned for hospital and institutional channels, where sterile formulation and manufacturing capabilities are important to product supply.
Consumer health
Over-the-counter and nutraceutical products
The company manufactures over-the-counter medicines and nutraceuticals in addition to prescription generics. These categories extend its business beyond institutional and prescription channels into consumer health, although specific brand names and product launches are not identified in the supplied reference material.
Controversies
2020
Strides Pharma recalls Tacrolimus capsules in the US
Strides Pharma Inc, a subsidiary of Strides Pharma Science, initiated a recall in the United States of 960 bottles of Tacrolimus capsules. The recall followed the FDA citing failed moisture limits for the product. The FDA classified the recall as Class III.
Brand decisions
2014
Amalgamation with Shasun PharmaceuticalsM&ABackground
Strides Arcolab and Shasun Pharmaceuticals sought to combine their businesses through a formal scheme of amalgamation.
Action taken
The boards of both companies approved the amalgamation scheme in September 2014.
Aftermath
Strides Arcolab subsequently changed its name to Strides Shasun, creating a new stage in the company's corporate development.
2013
Sale of Agila Specialties to MylanM&ABackground
Strides reviewed the ownership and structure of its specialty-pharmaceutical activities, including the Agila Specialties division.
Action taken
The company completed the sale of Agila Specialties to Mylan for total consideration of up to US$1.75 billion.
Aftermath
The transaction materially reshaped Strides' portfolio and separated the Agila business from the remaining company.
Total transaction consideration. Up to US$1.75 billion (2013)
Recent events
- Unconfirmed
Strides receives renewed EU GMP certificate for Puducherry facility[3]
Reported:
Strides Pharma Science said it received a renewed GMP certificate for its Puducherry facility after the EU GMP inspection was successfully closed.
Strides and Ennaid enter an exclusive manufacturing partnership[4]
Reported:
Strides Pharma Science announced that its wholly owned subsidiary Strides Pharma Global entered an exclusive partnership with Ennaid Therapeutics to produce an oral repurposed medication for COVID-19; Strides will be the product's exclusive manufacturing partner.
Strides Pharma recalls Tacrolimus capsules in the US[2]
Reported:
Strides Pharma Inc, a subsidiary of Strides Pharma Science, initiated a US recall of 960 bottles of Tacrolimus capsules after the FDA cited failed moisture limits. The FDA classified the recall as Class III.
Strides reports Q4FY20 and FY20 results[5]
Reported:
Strides Pharma Science announced its Q4 and FY20 results, reporting FY20 adjusted revenue of Rs. 29,127 million and adjusted EBITDA of Rs. 6,514 million. The company also recommended a dividend of Rs. 2 per share.
Strides commercializes favipiravir antiviral tablets[6]
Reported:
Strides Pharma Science announced that it had developed and commercialized favipiravir antiviral tablets in 200 mg and 400 mg strengths. The tablets were being exported to GCC countries, and Strides said it would apply to Indian drug authorities to begin studies and make the drug available in India.
Strides appoints R Ananthanarayanan as CEO and MD[7]
Reported:
Strides Pharma Science said its board appointed R Ananthanarayanan as Chief Executive Officer and Managing Director, effective January 9. He was to succeed Arun Kumar.
Sources8 sources
- 1Strides Pharma Scienceen.wikipedia.org
- 2Strides Pharma recalls Tacrolimus capsules in the USbusinesstoday.in
- 3Strides获得本地治里工厂续期EU GMP证书business-standard.com
- 4Strides与Ennaid建立独家制造合作business-standard.com
- 5Strides公布2020财年第四季度及全年业绩equitybulls.com
- 6Strides商业化推出法匹拉韦抗病毒片business-standard.com
- 7Strides 任命 R Ananthanarayanan 为首席执行官兼董事总经理business-standard.com
- 8Strides appoints Dr R Ananthanarayanan as CEO, MDbiospectrumindia.com
Cite this profile: Cite the canonical profile. /brand-wiki/strides-pharma-science · Editorial policy · How profiles are compiled